Tributyltin(IV)[3‐(3′,5′‐dimethylphenylamido)propanoate] as a potent HCV inhibitor, its delivery study, controlled release and binding sites using CTAB as a standard cell membrane

Shah, Farooq Ali; Fatima, Kaneez; Sabir, Shaista; Ali, Saqib; Qadri, Ishtiaq

doi:10.1002/aoc.3079

Cited by 4 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, organotin(IV) compounds have been found to be potent HCV inhibitors. 10 Organotin(IV) compounds have the ability to bind with RNA 11 and DNA 12 via electrostatic interaction of the Sn(IV) + moiety with the negatively charged oxygen of a phosphate group. 11 The single strand RNA provides greater accessibility to the Sn atom for interaction with nitrogenous bases as compared to double strand DNA and results in more stable Sn-RNA adducts as compared to Sn-DNA compounds.…”

Section: Introductionmentioning

confidence: 99%

Organotin(iv) based anti-HCV drugs: synthesis, characterization and biochemical activity

Shah

Sabir

Fatima³

et al. 2015

Dalton Trans.

Self Cite

View full text Add to dashboard Cite

Three new organotin(iv) carboxylates () of 3,5-dimethylbenzoate, have been synthesized and characterized by elemental analysis, FT-IR, multinuclear NMR ((1)H, (13)C and (119)Sn), mass spectrometry and single crystal X-ray structural analysis. Crystallographic data show that in compounds and , the geometry at the central Sn atom is skew-trapezoidal bipyramidal while compound displays a distorted trigonal bipyramidal coordination geometry. In the case of compounds and , the asymmetric chelating mode of the carboxylate groups is reflected in the unequal C-O bond distances, those observed for the O1 and O3 oxygen atoms being significantly longer than those found in the O2 and O4 atoms. In the case of compound , the carboxylate groups bridge asymmetrically adjacent tin atoms in an anti-syn mode generating polymeric zigzag chains running parallel to the crystallographic c-axis. The compounds were screened for anti-HCV (hepatitis C virus) potency by the Gaussia luciferase assay using infected Huh 7.5 cells (human hepatocellular cell). Structure-activity relationship studies led to the identification of dibutyltin(iv)bis(3,5-dimethylbenzoic acid) (compound ) as a potent HCV inhibitor, with log IC50 values equal to 0.69 nM in the cell-based assay. Compound was further subjected to quantitative analysis using real-time PCR assays and viral RNA count vs. drug concentration confirmed the Gaussia luciferase assay results. The HCV RNA targeting mode of the compounds () was confirmed by a compound-DNA interaction study. The compounds ()-DNA interactions were investigated by UV-vis spectroscopy and viscometry. The hypochromic effect in spectroscopy evidenced an intercalative mode of interaction with the binding affinity in the order of > > .

show abstract